Skip to main content
Erschienen in: BMC Infectious Diseases 1/2016

Open Access 01.12.2016 | Research article

National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals

verfasst von: Ashley Pechal, Kevin Lin, Stefan Allen, Kelly Reveles

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2016

Abstract

Background

Prior studies have demonstrated an increase in Clostridium difficile infection (CDI) incidence in the United States (U.S.) in recent years, but trends among different age groups have not been evaluated. This study describes national CDI incidence by age group over a 10-year period and mortality and hospital length of stay (LOS) among patients with CDI.

Methods

This was a retrospective analysis of the U.S. National Hospital Discharge Surveys from 2001 to 2010. Eligible patients with an ICD-9-CM discharge diagnosis code for CDI (008.45) were stratified by age: <18 years (pediatrics), 18–64 years (adults), and  ≥65 years (elderly adults). Data weights were used to derive national estimates. CDI incidence was calculated as CDI discharges/1000 total discharges. Mortality and LOS were compared between age groups using chi-square or Wilcoxon rank sum tests.

Results

These data represent 2.3 million hospital discharges for CDI over the study period. CDI incidence was highest among elderly adults (11.6 CDI discharges/1000 total discharges), followed by adults (3.5 CDI discharges/1000 total discharges) and pediatrics (1.2 CDI discharges/1000 total discharges). The elderly also had higher rates of mortality (8.8%) compared to adults (3.1%) and pediatrics (1.4%) (p < 0.0001). In addition, median hospital LOS was highest in the elderly (8 days) compared to adults (7 days) and pediatrics (6 days) (p < 0.0001).

Conclusions

CDI incidence among patients hospitalized in U.S. hospitals differed based on age group between 2001 and 2010. CDI incidence, mortality, and hospital LOS were highest in the elderly adult population.
Abkürzungen
AHRQ
Agency for Healthcare Research and Quality
CDC
Centers for Disease Control and Prevention
CDI
Clostridium difficile infection
LOS
Length of stay
NHDS
National Hospital Discharge Survey
PPI
Proton pump inhibitor

Background

Clostridium difficile is the most prevalent pathogen among healthcare-associated infections and recognized by the Centers of Disease Control and Prevention (CDC) as one of the top three urgent threats to public health [1, 2]. C. difficile infection (CDI) often presents as diarrhea, but can result in more severe clinical manifestations like toxic megacolon, intestinal perforation, and sepsis. Additionally, CDI can result in death (approximately 29,000 deaths in 2011) [3], prolonged patient hospital stays [46], and a marked increase in the economic burden on the healthcare system with mean attributable costs ranging from $8,911 to $30,049 per patient [7].
CDI incidence nearly doubled in United States (U.S.) community hospitals between 2001 and 2010 [8]. A similar report by the Agency for Healthcare Research and Quality (AHRQ) estimated that the number of hospitalizations due to CDI in the U.S. increased almost four times from 1993 to 2009 with the majority of cases affecting individuals 65 and older [9]. Prior studies have affirmed that CDI disproportionately affects the elderly, likely due to immunosuppression from advanced age or chronic comorbidities, more health care exposures, and greater antibiotic use [10, 11]. Despite this, it is unknown if incidence trends differ among age groups [3, 12]. Furthermore, trends in CDI health outcomes have not been explored by age group.
The objectives of this study were to: 1) identify national CDI incidence trends by age group and 2) describe mortality and hospital length of stay (LOS) among CDI patients by age group over a 10-year period.

Methods

This study utilized data from the CDC’s National Hospital Discharge Surveys (NHDS) from 2001 to 2010. The NHDS survey design and variable definitions have been described previously [13]. Several prior infectious diseases epidemiological studies, specifically evaluating healthcare-associated infections, have utilized NHDS data [8, 14, 15]. The UT Health Science Center San Antonio Institutional Review Board waived formal ethics approval and patient consent, as these data are publically available and do not contain any patient identifiers.
This was a retrospective analysis of patients discharged from U.S. hospitals from 2001 to 2010. Patients were included if they had any (principal or secondary) International Classification of Diseases, 9 th Revision, Clinical Modification (ICD-9-CM) discharge diagnosis code for CDI (008.45). The cohort was categorized into three age groups: pediatrics (<18 years), adults (18–64 years), and elderly adults (≥65 years).
Baseline patient demographics, as provided by the NHDS variable categories, were summarized using median (interquartile range) for continuous variables and counts (percentages) for categorical variables. Annual CDI incidence rates were calculated between 2001 and 2010 using CDI discharges in each age group as the numerator and total discharges in each age group as the denominator. Data weights were applied to derive national estimates. Patient mortality represented all-cause, in-hospital mortality and was identified by the “discharge status” variable of the NHDS. Hospital LOS was identified using the “days of care” variable of the NHDS.
CDI incidence was compared by age group using the z-score. Patient baseline characteristics, mortality, and hospital LOS were compared by age group using appropriate bivariable statistics (chi-square test for categorical variables and Wilcoxon rank sum test for continuous variables). JMP 10.0® (SAS Corp, Cary, NC) was used for all statistical comparisons.

Results

Baseline characteristics

Approximately 2.3 million CDI discharges over the study period were included for analysis. Table 1 describes the patients’ baseline demographics and hospital, payment, and admissions characteristics. Of these patients, 67.5% were elderly adults, 28.9% were adults, and 3.6% were pediatrics. The patient population was predominately female (58.7%) and White (85.6%), with a median (IQR) age of 74 (59–83) years. The median age for each group was as follows: pediatrics (6 years), adults (53 years), and elderly adults (80 years). Adult, elderly adult, and pediatric patients with CDI significantly differed with respect to patient sex, race, hospital size and ownership, principal payment source, and admission type and source (p < 0.0001 for all) (Table 1). The principal payment source was Medicare for 67% of patient discharges, as expected by the high proportion of elderly adult discharges in the study population. The primary admission source was through the emergency room for adults (60.3%) and elderly adults (59.8%); however; pediatric patients were more likely to be admitted by referral (39.2%).
Table 1
Baseline characteristics
Demographic
Overall
(n = 2,279,004)
Elderly
(n = 1,538,933)
Adults
(n = 657,513)
Pediatrics
(n = 82,558)
P-value*
Age (years), median (IQR)
74 (59–83)
80 (74-85)
52 (43-59)
5 (2–11)
<0.0001
Female sex
58.7%
61.5%
54.4%
39.4%
<0.0001
Race
 White
85.6%
89.6%
77.2%
78.7%
<0.0001
 Black
10.1%
7.0%
16.7%
14.8%
 Other
4.3%
3.4%
6.1%
6.5%
Hospital size
 6–99 beds
19.4%
22.6%
13.7%
5.6%
<0.0001
 100–199 beds
21.1%
21.6%
20.4%
19.1%
 200–299 beds
24.3%
24.8%
21.6%
36.1%
 300–499 beds
22.7%
20.7%
27.1%
25.1%
 500+ beds
12.5%
10.3%
17.2%
14.1%
Hospital ownership
 Proprietary
11.7%
13.5%
8.2%
5.7%
<0.0001
 Government
8.6%
6.8%
12.9%
8.0%
 Nonprofit
79.7%
79.7%
78.9%
86.3%
Principal payment source
 Medicare
67.0%
88.3%
25.9%
0.0%
<0.0001
 Medicaid
8.1%
1.3%
18.7%
50.9%
 Private
21.4%
9.2%
47.1%
43.1%
 Self-pay
1.6%
0.4%
4.6%
0.1%
 Other
1.9%
0.8%
3.7%
5.9%
Admission type
 Emergency
64.9%
66.4%
64.0%
41.5%
<0.0001
 Urgent
21.5%
19.9%
24.1%
33.4%
 Elective
13.4%
13.7%
11.9%
20.6%
 Newborn
0.2%
0.0%
0.0%
4.5%
Admission source
 Emergency room
59.3%
59.8%
60.3%
37.6%
<0.0001
 Transfer
15.1%
18.0%
8.8%
8.6%
 Referral
18.1%
15.7%
21.6%
39.2%
Other
7.5%
6.5%
9.3%
14.6%
IQR Interquartile range
*P-values reflect comparisons between elderly adult, adult, and pediatric CDI populations

CDI incidence by age group

Overall, CDI incidence significantly differed among age groups (p < 0.0001) (Table 2). CDI incidence was higher for elderly adults (11.6 CDI discharges/1000 total discharges), compared to adults (3.5 CDI discharges/1000 total discharges) and pediatric populations (1.2 CDI discharges/1000 total discharges). Elderly adults experienced the greatest change in CDI incidence over the study period (from 7.2 CDI discharges/1000 elderly adult discharges in 2001 to 13.7 CDI discharges/1000 elderly adult discharges in 2010) (Fig. 1). Among adults, CDI incidence increased over the study period, from 2.4 CDI/1000 adult discharges in 2001 to 4.3 CDI discharges/1000 adult discharges in 2010. CDI remained relatively unchanged among pediatrics over the study period (1.2 CDI/1000 pediatric discharges in 2001 and 2010).
Table 2
CDI incidence and health outcomes by age group
Outcome
Overall
Elderly
Adults
Pediatrics
P-value
CDI cases
2,279,004
1,538,933
657,513
82,558
--
CDI incidencea
4.5
11.6
3.5
1.2
<0.0001
Mortality
6.9%
8.8%
3.1%
1.4%
<0.0001
Hospital LOS
8 (4–14)
8 (5–14)
7 (4–14)
6 (3–16)
<0.0001
aCDI incidence calculated at CDI discharges per 1000 total discharges

Mortality and hospital LOS among patients with CDI by age group

The overall all-cause, in-hospital mortality was 6.9% and the median (IQR) hospital LOS was 8 (5–14) days. Mortality and hospital LOS significantly differed by age group (p < 0.0001 for each comparison). Mortality was higher for elderly adults (8.8%) as compared to adult (6.9%) and pediatric populations (3.1%) (p < 0.0001). Among those patients with CDI who died, the most common co-mortalities were septicemia (ICD-9-CM code 038.X; 35.7%), acute renal failure (ICD-9-CM code 584.X; 31.8%), pneumonia (ICD-9-CM codes 480–486.XX; 22.3%), and urinary tract infection (ICD-9-CM codes 599.0; 18.8%). Similar to mortality, median hospital LOS was longest for elderly adults (8 days), followed by adults (7 days), and pediatrics (6 days) (p < 0.0001). There were no differences between male and female elderly CDI patients for mortality (8.8% for both sexes) or median hospital LOS (8 days for both sexes).

Discussion

Prior national epidemiological investigations demonstrated considerable increases in CDI incidence over the last decade [3, 15, 16]; however, this is the first study to document the national burden of CDI longitudinally among different age groups. This report identified a disproportionate rise in CDI incidence among elderly adults, with an estimated 61% rate of increase from 2001 to 2010. Notably, elderly adults also suffered significantly higher all-cause, in-hospital mortality and increased hospital LOS compared to adult and pediatric patients.
Several factors could contribute to the disparate CDI incidence increase and health outcomes among the elderly compared to other age groups. Advanced patient age has been previously linked to an increase risk for CDI development. This is likely attributed to innate and iatrogenic changes such as: immunosenescence [17], higher prevalence of comorbid illness [18], changes in the gut flora [17], more healthcare exposures (e.g., hospitalizations and long-term care facility residence), and exposure to antibiotics [19] and other medications (e.g., proton pump inhibitors [PPIs]) [20]. In recent years, there has been an increase in the use of certain antibiotics, particularly among the elderly. Lee et al. [21] demonstrated an increase in overall antibiotic use in older adult patients by 30% and use of broad spectrum antibiotics in elderly adults by 68% from 2000 to 2010. Furthermore, two meta-analyses suggest that PPI use is associated with increased risk for CDI [22, 23]. Often, patients take PPIs inappropriately [24, 25]. Choudhry et al. [25] found that in a predominately elderly population (median age 76 years), more than half (53.4%) were prescribed a PPI without an appropriate indication. Furthermore, 7.9% were prescribed a PPI for unknown reasons. In addition, there has been a dramatic increase in the use of PPIs among outpatients in the U.S. A 2013 study by Rotman et al. [24] found that the use of PPIs more than doubled among outpatients in the U.S. between 2002 and 2009.
The poorer health outcomes among elderly patients with CDI could be due to several factors. First, the European and North American CDI guidelines report age over 65 years as a marker of severity [26, 27]. Severity of infection has been previously linked with increased patient mortality, as well as longer hospital LOS [28]. Additionally, a prior study demonstrated an increased risk of severe infection and death due to the more pathogenic C. difficile strain, BI/NAP1/027 strain in elderly adults compared to younger populations [29].
Our study findings are important for several reasons. First, in 2001, elderly adults represented approximately 13% of the U.S. population. During our study period, there was an addition of approximately five million elderly adults to the U.S. population [30]. By the year 2030, it is expected that elderly adults will grow to 19% of the total U.S. population. As the population ages, a greater proportion of Americans become high-risk for developing CDI. The incidence and health outcome trends elucidated in our study may help increase awareness of CDI, identify and protect high risk patients, and possibly reduce the occurrence of CDI in the hospital setting.

Conclusions

CDI incidence was highest among elderly adults at least 65 years of age, followed by adults and pediatric patients. The increase in CDI incidence among the elderly markedly outpaced that of the other two age group populations from 2001 to 2010. Additionally, elderly adults experienced higher all-cause, in-hospital mortality and longer hospitals stays as compared to adults and pediatrics patients.

Limitations

This study has potential limitations. First, this study was retrospective and relied on administrative coding to identify CDI cases rather than positive laboratory identification of C. difficile, which could result in misclassification bias. Although the use of ICD-9-CM codes to identify CDI has relatively high specificity (99.7%) and sensitivity (78%), it cannot be considered equivalent to medical chart review or microbiological analysis [31]. Importantly, our CDI case definition did not change over the study period; therefore, any coding error would persist throughout the study years and would have limited effects on CDI trends. Additionally, an initial CDI episode could not be discriminated from a recurrent CDI episode or readmission. Furthermore, there are factors that could have contributed to differences in CDI incidence and outcomes between age groups that we were not able to account for in our analyses including: antibiotic exposure, differences in CDI testing procedures, severity of comorbid illness, and C. difficile strain/ribotype. The exclusion of federal hospitals and long-term care hospitals in the NHDS and the lack of data after 2010 potentially limit the generalizability to those settings and may underestimate the burden of CDI in the U.S., particularly in recent years. Finally, the NHDS includes a large sample size, resulting in high study power. This limits the utility of p-values to establish differences among groups, as small variations are likely to be statistically significant.

Acknowledgements

None.

Funding

No funding was provided for the conduct of this study. KRR is supported by The University of Texas at Austin and the University of Texas Health Science Center at San Antonio Older Americans Independence Center Career Development (KL2) Program (1P30AG044271-01A1).

Availability of data and materials

Data from this study are publically available from the Centers for Disease Control and Prevention (http://​www.​cdc.​gov/​nchs/​nhds/​nhds_​questionnaires.​htm).

Authors’ contribution

All authors were involved in the study design, data interpretation, and drafting of the manuscript. Additionally, KR acquired the data and performed the statistical analyses. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.
Not applicable.

Declarations

The UT Health Science Center San Antonio Institutional Review Board waived formal ethics approval and patient consent.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–208.CrossRefPubMedPubMedCentral Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–208.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–34.CrossRefPubMed Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–34.CrossRefPubMed
4.
Zurück zum Zitat Aitken SL, Joseph TB, Shah DN, Lasco TM, Palmer HR, DuPont HL, Xie Y, Garey KW. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS ONE. 2014;9(7):e102848.CrossRefPubMedPubMedCentral Aitken SL, Joseph TB, Shah DN, Lasco TM, Palmer HR, DuPont HL, Xie Y, Garey KW. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS ONE. 2014;9(7):e102848.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Sammons JS, Localio R, Xiao R, Coffin SE, Zaoutis T. Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis. 2013;57(1):1–8.CrossRefPubMedPubMedCentral Sammons JS, Localio R, Xiao R, Coffin SE, Zaoutis T. Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis. 2013;57(1):1–8.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ. 2012;184(1):37–42.CrossRefPubMedPubMedCentral Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ. 2012;184(1):37–42.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Nanwa N, Kendzerska T, Krahn M, Kwong JC, Daneman N, Witteman W, Mittmann N, Cadarette SM, Rosella L, Sander B. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol. 2015;110(4):511–9.CrossRefPubMed Nanwa N, Kendzerska T, Krahn M, Kwong JC, Daneman N, Witteman W, Mittmann N, Cadarette SM, Rosella L, Sander B. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol. 2015;110(4):511–9.CrossRefPubMed
8.
Zurück zum Zitat Reveles KR, Lee GC, Boyd NK, Frei CR. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010. Am J Infect Control. 2014;42(10):1028–32.CrossRefPubMed Reveles KR, Lee GC, Boyd NK, Frei CR. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010. Am J Infect Control. 2014;42(10):1028–32.CrossRefPubMed
10.
Zurück zum Zitat Islam J, Cohen J, Rajkumar C, Llewelyn MJ. Probiotics for the prevention and treatment of Clostridium difficile in older patients. Age Ageing. 2012;41(6):706–11.CrossRefPubMed Islam J, Cohen J, Rajkumar C, Llewelyn MJ. Probiotics for the prevention and treatment of Clostridium difficile in older patients. Age Ageing. 2012;41(6):706–11.CrossRefPubMed
11.
Zurück zum Zitat Di Bella S, Capone A, Musso M, Giannella M, Tarasi A, Johnson E, Taglietti F, Campoli C, Petrosillo N. Clostridium difficile infection in the elderly. Infez Med. 2013;21(2):93–102.PubMed Di Bella S, Capone A, Musso M, Giannella M, Tarasi A, Johnson E, Taglietti F, Campoli C, Petrosillo N. Clostridium difficile infection in the elderly. Infez Med. 2013;21(2):93–102.PubMed
12.
Zurück zum Zitat Keller JM, Surawicz CM. Clostridium difficile infection in the elderly. Clin Geriatr Med. 2014;30(1):79–93.CrossRefPubMed Keller JM, Surawicz CM. Clostridium difficile infection in the elderly. Clin Geriatr Med. 2014;30(1):79–93.CrossRefPubMed
13.
Zurück zum Zitat Dennison C, Pokras R. Design and operation of the National Hospital Discharge Survey: 1988 redesign. Vital Health Stat 1. 2000;39:1–42. Dennison C, Pokras R. Design and operation of the National Hospital Discharge Survey: 1988 redesign. Vital Health Stat 1. 2000;39:1–42.
14.
Zurück zum Zitat Daniels KR, Frei CR. The United States’ progress toward eliminating catheter-related bloodstream infections: incidence, mortality, and hospital length of stay from 1996 to 2008. Am J Infect Control. 2013;41(2):118–21.CrossRefPubMed Daniels KR, Frei CR. The United States’ progress toward eliminating catheter-related bloodstream infections: incidence, mortality, and hospital length of stay from 1996 to 2008. Am J Infect Control. 2013;41(2):118–21.CrossRefPubMed
15.
Zurück zum Zitat McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006;12(3):409–15.CrossRefPubMedPubMedCentral McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006;12(3):409–15.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14(6):929–31.CrossRefPubMedPubMedCentral Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14(6):929–31.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkila J, Monti D, Satokari R, Franceschi C, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS ONE. 2010;5(5):e10667.CrossRefPubMedPubMedCentral Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkila J, Monti D, Satokari R, Franceschi C, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS ONE. 2010;5(5):e10667.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Tartof SY, Yu KC, Wei R, Tseng HF, Jacobsen SJ, Rieg GK. Incidence of polymerase chain reaction-diagnosed Clostridium difficile in a large high-risk cohort, 2011–2012. Mayo Clin Proc. 2014;89(9):1229–38.CrossRefPubMed Tartof SY, Yu KC, Wei R, Tseng HF, Jacobsen SJ, Rieg GK. Incidence of polymerase chain reaction-diagnosed Clostridium difficile in a large high-risk cohort, 2011–2012. Mayo Clin Proc. 2014;89(9):1229–38.CrossRefPubMed
19.
Zurück zum Zitat Owens Jr RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46 Suppl 1:S19–31.CrossRefPubMed Owens Jr RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46 Suppl 1:S19–31.CrossRefPubMed
20.
Zurück zum Zitat Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.CrossRefPubMedPubMedCentral Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Lee GC, Reveles KR, Attridge RT, Lawson KA, Mansi IA, Lewis 2nd JS, Frei CR. Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med. 2014;12:96.CrossRefPubMedPubMedCentral Lee GC, Reveles KR, Attridge RT, Lawson KA, Mansi IA, Lewis 2nd JS, Frei CR. Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med. 2014;12:96.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.CrossRefPubMed Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.CrossRefPubMed
23.
Zurück zum Zitat Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–10.CrossRefPubMed Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–10.CrossRefPubMed
25.
Zurück zum Zitat Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101(6):445–8.CrossRefPubMed Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101(6):445–8.CrossRefPubMed
26.
Zurück zum Zitat Bauer MP, Kuijper EJ, van Dissel JT, European Society of Clinical M, Infectious D. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15(12):1067–79.CrossRefPubMed Bauer MP, Kuijper EJ, van Dissel JT, European Society of Clinical M, Infectious D. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15(12):1067–79.CrossRefPubMed
27.
Zurück zum Zitat Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of A, Infectious Diseases Society of A. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.CrossRefPubMed Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of A, Infectious Diseases Society of A. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.CrossRefPubMed
28.
Zurück zum Zitat Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34(3):346–53.CrossRefPubMed Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34(3):346–53.CrossRefPubMed
29.
Zurück zum Zitat Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, Gardam M, McGeer A, Hutchinson J, Moore D, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis. 2010;50(2):194–201.CrossRefPubMed Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, Gardam M, McGeer A, Hutchinson J, Moore D, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis. 2010;50(2):194–201.CrossRefPubMed
31.
Zurück zum Zitat Dubberke ER, Reske KA, McDonald LC, Fraser VJ. ICD-9 codes and surveillance for Clostridium difficile-associated disease. Emerg Infect Dis. 2006;12(10):1576–9.CrossRefPubMedPubMedCentral Dubberke ER, Reske KA, McDonald LC, Fraser VJ. ICD-9 codes and surveillance for Clostridium difficile-associated disease. Emerg Infect Dis. 2006;12(10):1576–9.CrossRefPubMedPubMedCentral
Metadaten
Titel
National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals
verfasst von
Ashley Pechal
Kevin Lin
Stefan Allen
Kelly Reveles
Publikationsdatum
01.12.2016
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2016
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-2027-8

Weitere Artikel der Ausgabe 1/2016

BMC Infectious Diseases 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.